Ibex Investors’s Catalyst Pharmaceutical CPRX Stock Holding History

Ibex Investors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-42,098	Closed	-$215K	–	100
2019 Q1	$215K	Buy	+42,098	New	+$124K	0.02%	49

Other funds holding CPRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ibex Investors's CPRX Position: Q2 2019 in Review

Ibex Investors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2019, closing a stake of 42,098 shares — an estimated $215K sold.

Ibex Investors first reported a position in CPRX in Q1 2019 and held it in 1 quarter. The position peaked at $215K in Q1 2019. 101 funds tracked by Wall St. Rank hold CPRX as of Q2 2019.

Ibex Investors reported no remaining Catalyst Pharmaceutical position as of Q2 2019 after selling out during the quarter.
Ibex Investors sold 42,098 Catalyst Pharmaceutical shares in Q2 2019, an estimated $215K.
Ibex Investors first reported a position in Catalyst Pharmaceutical in Q1 2019 and held it in 1 quarter.
Ibex Investors's Catalyst Pharmaceutical position peaked at $215K in Q1 2019.
101 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2019.

Based on Ibex Investors's 13F filing for Q2 2019, filed 29 Jul 2019.